Market cap
$17 Mln
Revenue (TTM)
$48 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-22 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.5
-
Debt to Equity
1.4
-
Book Value
$0.6
-
EPS
$-0.7
-
Face value
--
-
Shares outstanding
36,725,900
10 Years Aggregate
CFO
$-94.79 Mln
EBITDA
$-86.19 Mln
Net Profit
$-126.98 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Chembio Diagnostics (CEMI)
| 106.8 | 16.7 | 30.0 | -27.8 | -69.2 | -43.6 | -20.6 |
|
BSE Sensex*
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Chembio Diagnostics (CEMI)
| -80.7 | -76.0 | 4.2 | -19.4 | -30.8 | 20.6 | 27.6 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Chembio Diagnostics (CEMI)
|
0.5 | 16.7 | 48.3 | -23.3 | -42.2 | -89.5 | -- | 0.7 |
| 25.0 | 2,375.4 | 12.9 | -113.6 | -993.9 | 133.4 | -- | 5.3 |
Shareholding Pattern
View DetailsAbout Chembio Diagnostics (CEMI)
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID 19, HIV and Syphilis, and Zika... virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, NEXT GENERATION DPP, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York. As of April 27, 2023, Chembio Diagnostics, Inc. operates as a subsidiary of Biosynex SA. Read more
-
Pres, CEO & Director
Mr. Richard L. Eberly
-
Pres, CEO & Director
Mr. Richard L. Eberly
-
Headquarters
Hauppauge, NY
-
Website
FAQs for Chembio Diagnostics (CEMI)
What is the current share price of Chembio Diagnostics Inc (CEMI) Today?
The share price of Chembio Diagnostics Inc (CEMI) is $0.46 (NASDAQ) as of 27-Apr-2023 16:00 EDT. Chembio Diagnostics Inc (CEMI) has given a return of -69.18% in the last 3 years.
What is the current PB & PE ratio of Chembio Diagnostics Inc (CEMI)?
Since, TTM earnings of Chembio Diagnostics Inc (CEMI) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.30
|
0.40
|
|
2021
|
-0.81
|
0.80
|
|
2020
|
-3.54
|
3.25
|
|
2019
|
-5.67
|
3.23
|
|
2018
|
-10.07
|
2.38
|
What is the 52 Week High and Low of Chembio Diagnostics Inc (CEMI)?
The 52-week high and low of Chembio Diagnostics Inc (CEMI) are Rs -- and Rs -- as of 17-May-2026.
What is the market cap of Chembio Diagnostics Inc (CEMI)?
Chembio Diagnostics Inc (CEMI) has a market capitalisation of $ 17 Mln as on 27-Apr-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Chembio Diagnostics Inc (CEMI)?
Before investing in Chembio Diagnostics Inc (CEMI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.